Welcome to our dedicated page for UMJA news (Ticker: UMJA), a resource for investors and traders seeking the latest updates and insights on UMJA stock.
Umoja Biopharma, Inc. (UMJA) is a clinical-stage biotechnology leader developing off-the-shelf immunotherapies through advanced in vivo gene editing and CAR T-cell platforms. This page provides investors and industry professionals with comprehensive updates on UMJA's progress in oncology and autoimmunity treatments.
Access real-time announcements including clinical trial milestones, strategic partnerships, manufacturing developments, and financial updates. Our curated news collection simplifies tracking UMJA's advancements in VivoVec technology and lentiviral vector production while maintaining compliance with biopharmaceutical regulations.
Key updates cover FDA communications, research collaborations, intellectual property developments, and production capacity expansions. Bookmark this page for streamlined monitoring of UMJA's progress in creating accessible cellular therapies and overcoming traditional treatment limitations.
Umoja Biopharma has announced a groundbreaking publication in the journal Blood, showcasing the first successful generation of in vivo CAR T-cells in a non-human primate (NHP) model. The data validate their VivoVec platform, demonstrating its potential to transform CAR T-cell therapies. Results indicated that VivoVec lentiviral particles could generate CAR+ T-cells targeting CD20 without lymphodepleting chemotherapy, leading to complete B-cell depletion for over 10 weeks. Key findings highlight the enhanced antitumor functionality of CAR T-cells generated via VivoVec particles, featuring a multidomain fusion protein. Umoja plans to initiate human trials in the latter half of 2024, aiming to improve treatment accessibility and effectiveness in oncology and autoimmunity.
